TRCT
ADVM

Tower Research Capital (TRC)’s Adverum Biotechnologies ADVM Stock Holding History

Tower Research Capital (TRC)’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,137
Closed -$4.59K – 5196
2025
Q2 		$4.59K Sell
2,137
-265
-11% -$741 ﹤0.01% 4295
2025
Q1 		$10.1K Sell
2,402
-1,960
-45% -$8.83K ﹤0.01% 3678
2024
Q4 		$20.4K Buy
4,362
+2,793
+178% +$18.8K ﹤0.01% 3170
2024
Q3 		$11K Buy
1,569
+108
+7% +$784 ﹤0.01% 3702
2024
Q2 		$10K Buy
1,461
+458
+46% +$4.26K ﹤0.01% 4185
2024
Q1 		$14.2K Buy
1,003
+934
+1,354% +$14.2K ﹤0.01% 3330
2023
Q4 		$520 Hold
69
– – ﹤0.01% 5550
2023
Q3 		$1.04K Sell
69
-881
-93% -$15.8K ﹤0.01% 5426
2023
Q2 		$15.1K Sell
950
-578
-38% -$6.08K ﹤0.01% 3646
2023
Q1 		$10K Sell
1,528
-986
-39% -$6.97K ﹤0.01% 4316
2022
Q4 		$15K Buy
2,514
+127
+5% +$963 ﹤0.01% 3396
2022
Q3 		$22K Buy
2,387
+1,593
+201% +$20.9K ﹤0.01% 3847
2022
Q2 		$10K Sell
794
-2,810
-78% -$29.4K ﹤0.01% 4422
2022
Q1 		$47K Buy
3,604
+2,848
+377% +$41.7K ﹤0.01% 2775
2021
Q4 		$13K Sell
756
-888
-54% -$17.8K ﹤0.01% 4143
2021
Q3 		$36K Sell
1,644
-61
-4% -$1.56K ﹤0.01% 3214
2021
Q2 		$60K Buy
1,705
+628
+58% +$33.8K ﹤0.01% 2870
2021
Q1 		$106K Buy
1,077
+262
+32% +$31.5K ﹤0.01% 2545
2020
Q4 		$88K Buy
815
+131
+19% +$16.2K ﹤0.01% 2466
2020
Q3 		$70K Sell
684
-142
-17% -$21.3K ﹤0.01% 3386
2020
Q2 		$173K Buy
+826
New +$146K 0.01% 1914
2020
Q1 		– Sell
-267
Closed -$31K – 2967
2019
Q4 		$31K Sell
267
-1,387
-84% -$122K ﹤0.01% 1643
2019
Q3 		$90K Buy
+1,654
New +$186K 0.01% 1415
2019
Q2 		– Sell
-175
Closed -$9K – 3596
2019
Q1 		$9K Sell
175
-745
-81% -$30.1K ﹤0.01% 2712
2018
Q4 		$29K Buy
+920
New +$37.4K ﹤0.01% 1648
2018
Q3 		– Sell
-19
Closed -$1K – 3707
2018
Q2 		$1K Sell
19
-742
-98% -$44.6K ﹤0.01% 3450
2018
Q1 		$44K Buy
+761
New +$47.4K ﹤0.01% 1741
2017
Q4 		– Sell
-362
Closed -$13K – 3456
2017
Q3 		$13K Buy
362
+60
+20% +$1.67K ﹤0.01% 2942
2017
Q2 		$8K Sell
302
-166
-35% -$4.54K ﹤0.01% 1701
2017
Q1 		$13K Buy
468
+209
+81% +$5.95K ﹤0.01% 1581
2016
Q4 		$8K Buy
259
+229
+763% +$7.48K ﹤0.01% 2758
2016
Q3 		$1K Sell
30
-453
-94% -$17.2K ﹤0.01% 3250
2016
Q2 		$15K Buy
483
+443
+1,108% +$20K ﹤0.01% 2458
2016
Q1 		$2K Sell
40
-44
-52% -$2.46K ﹤0.01% 3308
2015
Q4 		$8K Sell
84
-37
-31% -$3.25K ﹤0.01% 2373
2015
Q3 		$10K Buy
121
+33
+38% +$4.22K ﹤0.01% 2292
2015
Q2 		$14K Buy
88
+29
+49% +$9.78K ﹤0.01% 2395
2015
Q1 		$24K Buy
59
+29
+97% +$12.3K ﹤0.01% 2093
2014
Q4 		$16K Buy
30
+10
+50% +$3.85K ﹤0.01% 1738
2014
Q3 		$7K Buy
+20
New +$5.95K ﹤0.01% 3052

Other funds holding ADVM

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
PWA
Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return

Tower Research Capital (TRC)'s ADVM Position: Q3 2025 in Review

Tower Research Capital (TRC) sold out of Adverum Biotechnologies (ADVM) in Q3 2025, closing a stake of 2,137 shares — an estimated $4.59K sold.

Tower Research Capital (TRC) first reported a position in ADVM in Q3 2014 and held it in 40 quarters. The position peaked at $173K in Q2 2020. 50 funds tracked by Wall St. Rank hold ADVM as of Q3 2025.

  • Tower Research Capital (TRC) reported no remaining Adverum Biotechnologies position as of Q3 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 2,137 Adverum Biotechnologies shares in Q3 2025, an estimated $4.59K.
  • Tower Research Capital (TRC) first reported a position in Adverum Biotechnologies in Q3 2014 and held it in 40 quarters.
  • Tower Research Capital (TRC)'s Adverum Biotechnologies position peaked at $173K in Q2 2020.
  • 50 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2025, filed 14 Nov 2025.